JP2017538439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538439A5 JP2017538439A5 JP2017538915A JP2017538915A JP2017538439A5 JP 2017538439 A5 JP2017538439 A5 JP 2017538439A5 JP 2017538915 A JP2017538915 A JP 2017538915A JP 2017538915 A JP2017538915 A JP 2017538915A JP 2017538439 A5 JP2017538439 A5 JP 2017538439A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- item
- seq
- nodal
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 49
- 230000000694 effects Effects 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 15
- 201000001441 melanoma Diseases 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 3
- 210000000416 exudates and transudate Anatomy 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- -1 serum Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 239000003814 drug Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 3
- 208000021039 metastatic melanoma Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 101150101604 ACVR1B gene Proteins 0.000 description 1
- 102000002092 Left-Right Determination Factor Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 101000967919 Mus musculus Left-right determination factor 1 Proteins 0.000 description 1
- 102000044547 Nodal Human genes 0.000 description 1
- 108700024442 Nodal Proteins 0.000 description 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
- 102000057208 Smad2 Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060974P | 2014-10-07 | 2014-10-07 | |
| US62/060,974 | 2014-10-07 | ||
| PCT/US2015/054515 WO2016057683A2 (en) | 2014-10-07 | 2015-10-07 | Novel anti-nodal antibodies and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538439A JP2017538439A (ja) | 2017-12-28 |
| JP2017538439A5 true JP2017538439A5 (enExample) | 2018-11-08 |
| JP6574257B2 JP6574257B2 (ja) | 2019-09-11 |
Family
ID=55653941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538915A Active JP6574257B2 (ja) | 2014-10-07 | 2015-10-07 | 新規の抗Ｎｏｄａｌ抗体及びその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US9688750B2 (enExample) |
| EP (1) | EP3204414B1 (enExample) |
| JP (1) | JP6574257B2 (enExample) |
| WO (1) | WO2016057683A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| AU2014234314B2 (en) | 2013-03-21 | 2018-02-15 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| JP6574257B2 (ja) | 2014-10-07 | 2019-09-11 | アン アンド ロバート エイチ． ルーリー チルドレンズ ホスピタル オブ シカゴ | 新規の抗Ｎｏｄａｌ抗体及びその使用方法 |
| WO2018127494A1 (en) * | 2017-01-03 | 2018-07-12 | Deinobiotics | Methods of producing lipolanthipeptides |
| US11331019B2 (en) | 2017-08-07 | 2022-05-17 | The Research Foundation For The State University Of New York | Nanoparticle sensor having a nanofibrous membrane scaffold |
| US20190365922A1 (en) * | 2018-06-05 | 2019-12-05 | University Of Mississippi Medical Center | Method for the production of precisely sized macro- and micro-elp containing particles for the delivery of therapeutic agents |
| EP3827116A4 (en) | 2018-07-23 | 2022-05-11 | The Governors of the University of Alberta | Genetically-encoded bicyclic peptide libraries |
| WO2020154215A1 (en) * | 2019-01-26 | 2020-07-30 | Chien, Du-Shieng | Nodal regulation of cancer drug resistance gene |
| US20230310478A1 (en) * | 2020-09-02 | 2023-10-05 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of pulmonary hypertension and cancer |
| KR102763290B1 (ko) * | 2021-09-16 | 2025-02-05 | 동아대학교 산학협력단 | 신규한 샤르코-마리-투스병 제1a형 진단 또는 예후 예측용 바이오마커 및 이의 용도 |
| CN119592689A (zh) * | 2024-11-19 | 2025-03-11 | 北京肿瘤医院(北京大学肿瘤医院) | SMAD2、p38 MAPK作为评估免疫治疗黏膜黑色素瘤效果的标志物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1993003151A1 (en) | 1991-08-10 | 1993-02-18 | Medical Research Council | Treatment of cell populations |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US20020086351A1 (en) * | 1998-08-20 | 2002-07-04 | Reinhard Ebner | Human nodal and lefty homologues |
| JP5693004B2 (ja) | 2006-07-28 | 2015-04-01 | チルドレンズ メモリアル ホスピタル | ヒト胚性幹細胞の微小環境を使用して腫瘍細胞の悪性度を抑制する方法 |
| WO2009051220A1 (ja) * | 2007-10-19 | 2009-04-23 | Immunas Pharma, Inc. | Aβオリゴマーに特異的に結合する抗体およびその利用 |
| EP2225200B1 (en) | 2007-12-24 | 2013-10-16 | DSM IP Assets B.V. | Convergent synthesis of renin inhibitors and intermediates useful therein |
| JP2012504961A (ja) * | 2008-10-06 | 2012-03-01 | ミネルバ バイオテクノロジーズ コーポレーション | Ｍｕｃ１＊抗体 |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| DK2488867T3 (da) * | 2009-10-14 | 2020-11-09 | Janssen Biotech Inc | Fremgangsmåder til affinitetsmodning af antistoffer |
| CN108383909B (zh) * | 2012-02-24 | 2021-08-24 | 艾伯维施特姆森特克斯有限责任公司 | 抗sez6抗体及使用方法 |
| JP6574257B2 (ja) | 2014-10-07 | 2019-09-11 | アン アンド ロバート エイチ． ルーリー チルドレンズ ホスピタル オブ シカゴ | 新規の抗Ｎｏｄａｌ抗体及びその使用方法 |
-
2015
- 2015-10-07 JP JP2017538915A patent/JP6574257B2/ja active Active
- 2015-10-07 WO PCT/US2015/054515 patent/WO2016057683A2/en not_active Ceased
- 2015-10-07 EP EP15849199.3A patent/EP3204414B1/en active Active
- 2015-10-07 US US14/877,617 patent/US9688750B2/en active Active
-
2017
- 2017-06-27 US US15/634,355 patent/US10508147B2/en active Active
-
2018
- 2018-02-13 US US15/895,771 patent/US10494428B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538439A5 (enExample) | ||
| CN103562403B (zh) | 一个识别肿瘤起始细胞的抗体和抗原及其应用 | |
| JP2020500003A5 (enExample) | ||
| US20200157218A1 (en) | Bispecific antibodies to ror1 and cd3 | |
| JP2020534830A5 (enExample) | ||
| JP2010523096A5 (enExample) | ||
| US9683032B2 (en) | Anti-S100A4 antibody molecules and their uses | |
| AU2020293160B2 (en) | Anti-CD25 antibody and application thereof | |
| US20220119546A1 (en) | Plectin-1 binding antibodies and uses thereof | |
| KR20170039074A (ko) | Tmcc3의 억제에 의한 암 저해 방법 | |
| CN112243443A (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
| JP6977105B2 (ja) | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 | |
| WO2012063839A1 (ja) | 抗１本鎖ｉｖ型コラーゲンポリペプチド抗体、並びに該抗体を含む医薬、及び腫瘍の診断薬、予防薬、又は治療薬 | |
| JP7086607B2 (ja) | Ｉｇｆ－１ｒ抗体および癌の診断のためのその使用 | |
| US20210253691A1 (en) | Methods for improving response to anti-lif antibody treatment in individuals with cancer | |
| CN121008043A (zh) | Axl-gas6复合物的检测方法及在心肌梗死患者中的应用 | |
| CN120058950A (zh) | 抗adam9的抗体及其用途 | |
| CN118994393A (zh) | 一种抗fgfr2抗体及其应用 | |
| CN121108358A (zh) | 一种抗gpc3×cd3双特异性抗体及其制备方法和用途 | |
| CN118591554A (zh) | 抗人cxcl1抗体 | |
| HK40036076B (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof | |
| HK40036076A (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof | |
| HK1248730B (zh) | Igf-1r抗体及其用於癌症诊断的用途 | |
| HK1243434B (zh) | Igf-1r抗体及其诊断癌症的用途 | |
| BR112017022635B1 (pt) | Anticorpo anti-igf-1r, kits, e métodos para a detecção in vitro ou ex vivo da presença e/ou localização de células tumorais expressando igf-1r em um indivíduo, para a detecção in vitro ou ex vivo da percentagem de células tumorais que expressam igf-1r em um indivíduo, para a determinação in vitro ou ex vivo do nível de expressão de igf-1r em células tumorais em um indivíduo, para a determinação in vitro ou ex vivo da pontuação de igf-1r de células tumorais ou de um tumor em um indivíduo, para determinar se um transtorno oncogênico é suscetível ao tratamento com uma droga de anticorpo tendo como alvo a via de igf-1r, para a determinação in vitro ou ex vivo da eficácia de um regime terapêutico conce(...) |